Last reviewed · How we verify
Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients
NCT00347503
Phase 4
COMPLETED
Evaluation of the aqueous concentrations of 2 topical NSAIDS as well as the PGE2 inhibition in human patients.
Details
| Lead sponsor | Innovative Medical |
|---|
| Phase | Phase 4 |
|---|
| Status | COMPLETED |
|---|
Conditions
Interventions
- ketorolac 0.4%, bromfenac 0.09%
Countries
United States